Revenue
2012
2013
2020
2022
2023
2024
2025
Oncotelic Therapeutics, Inc. (OTLC)
Price$0.03134Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2014
2015
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $70,000 | $0 | — | $1.7M | — | — | — | — | — | — | $95,000 | $156,000 | — | — | — |
| Research & development | $4,357 | $0 | $61,143 | $756,910 | $3.7M | $4.3M | $1.4M | $649,755 | $10.5M | $8.8M | $9.1M | $7.4M | $3.6M | $3.5M | $5.3M | $12.1M | $22.3M |
| Operating expenses | $3.2M | $3.6M | $6.7M | $9.7M | $9.1M | $9.3M | $4.3M | $712,738 | $13.8M | $13.8M | $13.7M | $12.7M | $8.4M | $8.2M | $11.9M | $18.5M | $31.2M |
| Operating income | −$3.2M | −$3.6M | −$6.6M | −$9.7M | −$9.1M | −$7.6M | −$4.3M | −$712,738 | −$13.8M | −$13.8M | −$13.7M | −$12.7M | −$8.3M | −$8.1M | −$11.9M | −$18.5M | −$31.2M |
| Operating margin | — | — | −9,497.16% | — | — | −435.69% | — | — | — | — | — | — | −8,715.79% | −5,174.36% | — | — | — |
| EBITDA | $361.5M | −$3.9M | −$7.2M | $7.7M | −$9.1M | −$7.2M | −$4.3M | −$676,549 | −$13.8M | −$13.7M | −$13.7M | −$11.1M | −$8.3M | −$8.0M | −$11.8M | −$18.4M | −$31.0M |
| EBITDA margin | — | — | −10,230.40% | — | — | −414.77% | — | — | — | — | — | — | −8,694.95% | −5,150.58% | — | — | — |
| Net income | $249.3M | −$4.5M | −$7.9M | $5.1M | −$9.4M | −$9.5M | −$6.6M | −$712,738 | −$13.8M | −$13.7M | −$13.7M | −$12.6M | −$8.3M | −$8.1M | −$9.7M | −$23.8M | −$24.7M |
| Net profit margin | — | — | −11,290.13% | — | — | −545.86% | — | — | — | — | — | — | −8,712.63% | −5,178.85% | — | — | — |
| Basic EPSper basic share | $0.59 | $0.01 | -$0.02 | $0.01 | -$0.03 | -$0.11 | -$0.11 | -$0.12 | -$0.52 | -$0.51 | -$0.54 | -$0.75 | -$4.67 | -$5.48 | -$10.37 | -$71.60 | -$1,908.84 |
| Diluted EPSper diluted share | $0.59 | -$0.01 | -$0.02 | $0.01 | -$0.03 | -$0.11 | -$0.11 | -$0.12 | -$0.52 | -$0.51 | -$0.54 | -$0.75 | -$4.67 | -$5.48 | -$10.37 | -$71.60 | -$1,908.84 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Trieu Vuong | 117.54M |
Shah Amit B. | 378.84K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2026Form 4 | Trieu VuongCHAIRMAN AND CEO | BuyCommon Stock | 115.0K | $0.05 | $5.8K | 93.88M |
| Jun 23, 2026Form 4 | Trieu VuongCHAIRMAN AND CEO | BuyCommon Stock | 75.0K | $0.05 | $3.8K | 93.77M |
| Jun 22, 2026Form 4 | Trieu VuongCHAIRMAN AND CEO | BuyCommon Stock | 65.0K | $0.05 | $3.3K | 93.69M |
| Jun 22, 2026Form 4 | Shah Amit B.CFO | BuyCommon Stock | 20.0K | $0.05 | $1.0K | 378.8K |
| Jun 17, 2026Form 4 | Trieu VuongCHAIRMAN AND CEO | BuyCommon Stock | 239.8K | $0.04 | $9.6K | 93.63M |